Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Rating of "Moderate Buy" by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine research firms that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $50.11.

A number of research analysts recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Celldex Therapeutics in a report on Friday, June 13th. Morgan Stanley decreased their target price on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Canaccord Genuity Group assumed coverage on Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price target for the company. UBS Group reduced their price target on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, The Goldman Sachs Group reduced their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research note on Friday, May 9th.

Institutional Trading of Celldex Therapeutics

A number of institutional investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Celldex Therapeutics by 1.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company's stock valued at $798,000 after acquiring an additional 680 shares during the period. Invesco Ltd. lifted its position in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after acquiring an additional 871 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 878 shares during the last quarter. Values First Advisors Inc. lifted its position in shares of Celldex Therapeutics by 3.2% during the 1st quarter. Values First Advisors Inc. now owns 29,933 shares of the biopharmaceutical company's stock worth $550,000 after buying an additional 924 shares during the last quarter. Finally, Swiss National Bank lifted its position in shares of Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock worth $2,964,000 after buying an additional 1,400 shares during the last quarter.

Celldex Therapeutics Trading Up 0.7%

Shares of NASDAQ:CLDX traded up $0.16 during trading on Wednesday, hitting $23.14. 265,458 shares of the company were exchanged, compared to its average volume of 960,657. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of -8.59 and a beta of 1.13. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The firm has a fifty day moving average price of $20.72 and a two-hundred day moving average price of $21.06.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). The business had revenue of $0.70 million for the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative return on equity of 23.46% and a negative net margin of 2,366.07%. As a group, research analysts predict that Celldex Therapeutics will post -2.48 EPS for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.